Rainbow Extension Study

PHASE3CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

June 16, 2016

Primary Completion Date

April 21, 2022

Study Completion Date

April 21, 2022

Conditions
Retinopathy of Prematurity (ROP)
Interventions
DRUG

Ranibizumab

1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required

Trial Locations (73)

1090

Novartis Investigative Site, Vienna

1125

Novartis Investigative Site, Budapest

2100

Novartis Investigative Site, Koebenhavn Ø

4032

Novartis Investigative Site, Debrecen

8000

Novartis Investigative Site, Bruges

9000

Novartis Investigative Site, Ghent

10000

Novartis Investigative Site, Zagreb

10002

Novartis Investigative Site, Taipei

10138

Novartis Investigative Site, Tallinn

11211

Novartis Investigative Site, Riyadh

12808

Novartis Investigative Site, Prague

13915

Novartis Investigative Site, Marseille

14642

Novartis Investigative Site, Rochester

14700

Novartis Investigative Site, Praha 4 - Podoli

21131

Novartis Investigative Site, Alexandria

21201

Novartis Investigative Site, Baltimore

26480

Novartis Investigative Site, Meselik

26506

Novartis Investigative Site, Morgantown

30625

Novartis Investigative Site, Hanover

33305

Novartis Investigative Site, Taoyuan District

34140

Novartis Investigative Site, Istanbul

40202

Novartis Investigative Site, Louisville

48105

Novartis Investigative Site, Ann Arbor

50139

Novartis Investigative Site, Florence

50586

Novartis Investigative Site, Kuala Lumpur

60612

Novartis Investigative Site, Chicago

78705

Novartis Investigative Site, Austin

80045

Novartis Investigative Site, Aurora

80054

Novartis Investigative Site, Amiens

88996

Novartis Investigative Site, Kota Kinabalu

95817

Novartis Investigative Site, Sacramento

110029

Novartis Investigative Site, New Delhi

127486

Novartis Investigative Site, Moscow

194100

Novartis Investigative Site, Saint Petersburg

300041

Novartis Investigative Site, Timișoara

380016

Novartis Investigative Site, Ahmedabad

420012

Novartis Investigative Site, Kazan'

428028

Novartis Investigative Site, Cheboksary

500025

Novartis Investigative Site, Brasov

625020

Novartis Investigative Site, Madurai

641014

Novartis Investigative Site, Coimbatore

695035

Novartis Investigative Site, Vanchiyoor

A-8036

Novartis Investigative Site, Graz

708 52

Novartis Investigative Site, Ostrava

115 27

Novartis Investigative Site, Ampelokipoi

Novartis Investigative Site, Athens

564 03

Novartis Investigative Site, Thessaloniki

400 008

Novartis Investigative Site, Mumbai

06100

Novartis Investigative Site, Perugia

00054

Novartis Investigative Site, Fiumicino

00168

Novartis Investigative Site, Roma

453-8511

Novartis Investigative Site, Nagoya

466 8560

Novartis Investigative Site, Nagoya

276-8524

Novartis Investigative Site, Yachiyo

812-8582

Novartis Investigative Site, Fukuoka

814 0180

Novartis Investigative Site, Fukuoka

830-0011

Novartis Investigative Site, Kurume

Unknown

Novartis Investigative Site, Sapporo

765-8507

Novartis Investigative Site, Zentsujichó

901-1303

Novartis Investigative Site, Shimajiri-Gun

594-1101

Novartis Investigative Site, Izumi

520-2192

Novartis Investigative Site, Ohtsu-city

183-8561

Novartis Investigative Site, Fuchū

143 8541

Novartis Investigative Site, Ōta-ku

157-8535

Novartis Investigative Site, Setagaya-ku

130-8575

Novartis Investigative Site, Sumida-ku

170-8476

Novartis Investigative Site, Toshima-ku

LT 50161

Novartis Investigative Site, Kaunas

020395

Novartis Investigative Site, Bucharest

833 40

Novartis Investigative Site, Bratislava

07100

Novartis Investigative Site, Soguksu / Antalya

M13 9WL

Novartis Investigative Site, Manchester

PO6 3LY

Novartis Investigative Site, Portsmouth

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY